Synairgen Share Discussion Threads

[d1nga] 25/4/2020 15:30

Thanks Nobby

Same info from who

[nobbygnome] 25/4/2020 15:18

Yes because it means it is difficult to make antibodies or other immune responses which neutralise the virus and which last for a long time.

[d1nga] 25/4/2020 14:35

Does this mean that a treatment rather than a vaccine is the way forward?

I'm an engineer and not a scientist

:-)

[toffeeman] 25/4/2020 13:35

That is a supernumeric assumption :)

[supernumerary] 25/4/2020 11:49

I think we're all familiar with the reproducibility debate - you just have to take the best evidence available at the time, weigh it carefully, then check. That said, I'm not looking forward to settling down with a 76pp biotech pdf... perhaps later, if it rains :)

[toffeeman] 25/4/2020 11:44

I would assume that a significant number of those on the trial were already taking a prescribed ACE for hypertension and so we should see whether or not the finding in the paper generalises.

[nobbygnome] 25/4/2020 11:36

There are many coronaviruses which do it but yes the SARS virus is one of them. Plus also there is evidence that patients who have a deficiency in interferon production are more susceptible to the disease. So it depends which evidence you take notice of.

And as a scientist you don't necessarily believe the conclusion of any paper even a peer reviewed one. There are a couple of conspicuous examples in my field where peer reviewed papers were completely and utterly wrong. There was one long string of papers in the field of Crohns Disease where my group disproved what had been published before by a number of groups. Before we disproved the phenomenon, the results were talked about all the time but nobody ever talks about them now.

[supernumerary] 25/4/2020 11:28

The paper isn't peer-reviewed, but given the number of authors I think we have to believe its conclusions are broadly correct.

Presumably different coronaviruses behave differently in this way? Nobby - when you refer to 'Covid viruses inhibit interferon production' you're referring to SARS and MERS?

[nobbygnome] 25/4/2020 11:18

That is the first time I have seen that suggestion and most other data would suggest the exact opposite. Covid viruses inhibit interferon production which suggests that it is damaging to them. Evolution is an amazing process....

Ultimately proving the science is what it's all about. As a scientist you construct a hypothesis on the current evidence until new data becomes available. Then you adjust or amend your hypothesis based on the new evidence. That is how science works.

[supernumerary] 25/4/2020 11:12

This is the original paper:



Very long - 76pp! - so only for the truly dedicated. The abstract is below - the final paragraph is worthy of attention. A comment from NobbyG would be appreciated.

--------
[Edited for legibility]

Summary

There is pressing urgency to understand the pathogenesis of the severe acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2) which causes the disease COVID-19. SARS-CoV2 spike (S)-protein binds ACE2, and in concert with host proteases, principally TMPRSS2, promotes cellular entry. The cell subsets targeted by SARS-CoV-2 in host tissues, and the factors that regulate ACE2 expression, remain unknown.

Here, we leverage human, non-human primate, and mouse single-cell RNA-sequencing (scRNA-seq) datasets across health and disease to uncover putative targets of SARS-CoV-2 amongst tissue-resident cell subsets. We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells.

Strikingly, we discover that ACE2 is a human interferon stimulated gene (ISG) in vitro using airway epithelial cells, and extend our findings to in vivo viral infections. Our data suggest that SARS-CoV-2 could exploit species-specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection.

[nobbygnome] 25/4/2020 11:11

The injected route is bound to result in more systemic effects because you are giving a much larger dose to the whole body. By the inhaled route you are giving the drug exactly to the part of the body where you want it to work.

[lauders] 25/4/2020 11:02

You and others are welcome John1972. I try to be level-headed and not ramp or trash like others. Very interesting to note per the video that Amati Global Investors VCT buy for the long term and are not traders. That seems pretty positive to me.

[2nell] 25/4/2020 10:59

The inhaled route is surely different than being injected,which the report seems to be based on.

[rothchildsbutler] 25/4/2020 10:50

Lika that report is not great. It also suggests interferon may give the virus more cells to attack?

[john1972] 25/4/2020 10:49

Lauders...... Brilliant! This is just the sort of research and information that should be shared via these chat boards. Thanks

[likya123] 25/4/2020 10:24

From lse board...




This is good and another reason SNG001 will be critical in the treatment of Covid19. 

Spread the word people

[2nell] 25/4/2020 10:23

More new research Interferon will work.Link from poster on LSE

hxxps://www.sciencedaily.com/releases/2020/04/200422132556.htm

[lauders] 25/4/2020 08:03

SNG gets a nice short mention in this piece (6.30 minutes/seconds in):



Amati Global Investors AIM VCT might be something to check out in greater detail too.



From their March 2020 report:

We made four qualifying investments during the month. They were additional to existing holdings, each of which we had been hoping to be able to allocate more capital to, and each of which was able to raise more money that they originally sought, leaving them well funded for the future: Diurnal, a drug development company with two products aimed at treating adrenal insufficiency; Ilika, a leading developer of solid state batteries; and Polarean Imaging, which is commercialising a transformational new lung imaging technology. We also made one investment in a new company, Synairgen, in order to help fund a rapid clinical trial for its lead product (an inhaled form of Interferon Beta) to be used to mitigate the effects of COVID-19. Interferon Beta is used by the body to control immune responses, and it is believed it is lacking in patients more vulnerable to COVID-19. This inhaled form of the drug will deliver it exactly where it is needed, so it seemed compelling to help ensure that this trial could go ahead as quickly as possible.

[amaretto1] 25/4/2020 07:19

U looked at C4XD .... I'm hearing they are sat on something blockbuster ...Big pharma collaboration.

[nobbygnome] 25/4/2020 07:11

Yes I know it was my fault but let's get back to talking about SNG.

A month or so to go for results which might change the course of the crisis!

[parob] 25/4/2020 07:06

SNG SBTX and OPTI holder too! Pharma, biotech and microbiome stocks should do well over the next few years - seems to be more money flowing into these sectors on the back of Coronavirus. I mentioned SBTX (skin microbiome stock) on this board on the 14th April (post 3549). Since then it has risen 75% but momentum is with it and it could charge much higher imo.

[rafboy] 24/4/2020 22:53

As it’s the weekend I can endorse what Nobby says. OPTI is a growth company gaining traction across many countries. A quick review of recent RNS’s will give you a good indication of the number and quality of the deals it has signed.

SNG is my second largest holding after OPTI.